We then treated TMZ-resistant glioma cells with the specific inhibitor to AKT, MK2206, and found that MK2206 treatment significantly suppressed phosphorylation of CDKN1A at Ser473 (Figure 6B). This evidence concerns the gene AKT1 and central nervous system cancer.